Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
Healthcare
$1.79 +2.35%
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
52W Low $3.27High $6.95
Volume 0.53M
Average 0.15M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$86.10M
FY 2025 · Annual
Investing Cash Flow
$112.04M
FY 2025 · Annual
Financing Cash Flow
$1.02M
FY 2025 · Annual
-99.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Depreciation & Amortization | 3.23M | 7.9M | 3.45M | 3.12M | 3.33M |
| Deferred Income Tax | 1.41M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.38M | 0 | 16.19M | 11.89M | 10.4M |
| Change in Working Capital | 33.44M | 281.55M | (41.88M) | (32.27M) | (32.14M) |
| Accounts Receivables | (300M) | 300M | 0 | 0 | 0 |
| Inventory | (3.17M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 135K | 1.61M | 846K | (2.48M) | 481K |
| Other Working Capital | 336.48M | (20.07M) | (42.73M) | (29.79M) | (32.62M) |
| Other Non-Cash Items | 4.61M | 13.05M | 2.56M | 3.47M | 6.59M |
| Operating Cash Flow | (50.25M) | 193.61M | (118.11M) | (100.41M) | (86.1M) |
| Capital Expenditures | (3.31M) | (1.21M) | (1.22M) | (906K) | (50K) |
| Acquisitions (Net) | (39.49M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (99.98M) | (409.35M) | (73.9M) | (261.47M) | (131.25M) |
| Sales of Investments | 139.47M | 166.23M | 219.58M | 232.47M | 243.34M |
| Other Investing Activities | 39.49M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 36.17M | (244.32M) | 144.45M | (29.9M) | 112.04M |
| Debt Repayment | (21.21M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 42.21M | 1.76M | 0 | 103.4M | 1.02M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.42M | 0 | 1.78M | 2.03M | 0 |
| Financing Cash Flow | 22.42M | 1.76M | 1.78M | 105.43M | 1.02M |
| Effect of Forex Changes | 0 | 25K | 0 | 0 | 0 |
| Net Change in Cash | 8.34M | (48.92M) | 28.12M | (24.88M) | 26.96M |
| Free Cash Flow | (53.56M) | 192.4M | (119.33M) | (101.31M) | (86.15M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$74.3M
+ D&A$3.3M
+ Stock-Based Comp$10.4M
+ Deferred Tax$0
- Working Capital-$32.1M
+ Other Non-Cash$6.6M
= Operating Cash Flow-$86.1M
- Capex-$50.0K
= Free Cash Flow-$86.1M
Analysis
FY2025 free cash flow is -$86.1M. FCF conversion is 116.0% of net income. Operating cash flow was -$86.1M, with capex of -$50.0K. The largest bridge item is Working Capital at -$32.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 5, 2026 | |
| 8-K | Current report | Oct 1, 2026 |
Does FHTX generate free cash flow?
Foghorn Therapeutics Inc. (FHTX) generated -$86.15M of free cash flow in fiscal 2025.
How much operating cash flow does FHTX produce?
Operating cash flow was -$86.10M, before capital expenditures of $50,000.00.
Continue the stock analysis
Jump to another research area for this company.